SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: ghmm who wrote (456)2/3/2009 9:43:16 AM
From: rkrw  Read Replies (1) | Respond to of 508
 
But there would have been half as many placebo patients in the 2nd trial.

I think it has a shot at approval, the lack of alternatives and poor prognosis will help. I think they need explanations for the .50 though. If the 80% in the US was capacity 2 that may help.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News